Renovaro Completes Merger with BioSymetrics to Strengthen AI-Based Biomarker Discovery and Precision Medicine
Thursday, April 10, 2025
Renovaro Biosciences Inc, a TechBio company specialising in advanced diagnostics, drug discovery, and genetically enhanced cancer therapies, has finalised its previously announced merger with BioSymetrics. The transaction was completed on 8 April 2025.
BioSymetrics is known for its expertise in artificial intelligence (AI)-driven drug discovery and precision neurology. The merger is expected to expand Renovaro’s capabilities in biomarker discovery and data analysis, while also introducing in vivo validation and additional drug discovery tools to its AI-powered platform.
Central to this collaboration is BioSymetrics’ proprietary Elion platform, which applies AI and machine learning to identify complex biological links, helping to accelerate the development of new diagnostics and treatments. The company’s Phenograph system helps to map clinical data to therapeutic targets, improving the identification of biomarkers and enabling patient segmentation and drug repurposing.
BioSymetrics also brings advanced in vivo modelling and machine vision systems that support high-throughput phenotypic screening. These technologies use AI to detect subtle biological responses with high accuracy. Over time, the company has built an extensive database from in vivo experiments, including behavioural and morphological analyses. This combined computational and experimental approach is designed to speed up the validation of new treatments and has already led to collaborations with companies such as Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
With the integration of the Elion platform into Renovaro’s operations, the merged company plans to accelerate the translation of biomarker data into faster discovery timelines, improving the accuracy of target identification and overall research efficiency. This is expected to contribute to quicker and more effective drug development in both oncology and neurology.
The merger reflects a shared commitment to using AI and data-driven strategies to support precision medicine. Going forward, the combined organisation will focus on uniting AI-powered biomarker discovery with innovative drug development, aiming to deliver more targeted and effective treatments to patients globally.
Source: globenewswire.com
